Zerigo Health, formerly known as Clarify Medical, a connected skin therapy device, raised $43 million in a Series B funding round led by 7wireVentures.
New investors General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, Leaps by Bayer, existing investors SV Health Investors, H.I.G. Capital and Bluestem Capital also participated.
As part of the investment, Glen Tullman, managing partner of 7wireVentures, CEO of Transcarent, and former CEO of Livongo will join the company’s board.
“As the first connected phototherapy solution, Zerigo Health is empowering people to better manage their chronic skin conditions from the comfort of home or any location they choose, while also helping to significantly reduce costs associated with legacy treatment methods and expensive therapeutics,” said Tullman.
“7wireVentures is excited to lead the company’s latest funding round as it rapidly drives adoption of its solution among self-insured employers, health plans, and their employees and members.”
Zerigo Health offers a connected skin therapy device. The device is used to treat skin conditions like psoriasis, vitiligo, and eczema. Patients can use their devices according to their doctors’ prescriptions.
Zerigo Health received FDA clearance for its device in 2017 and launched it to the public in 2018.
Including the latest funding round, Zerigo Health has raised over $60 million to date. The company raised $18 million in Series A funding in 2019.
“At such an exciting time in the company’s development, we are fortunate and excited to welcome our new and existing Series B investors, as well as Glen Tullman as our new Executive Chairman,” said John E. Schellhorn – President and CEO of Zerigo Health.
“Zerigo Health continues to gain traction in the market and is well-positioned to meet the growing demand by patients to be able to treat their chronic skin conditions wherever they may be. This new investment capital will help fuel our growth in the health plan and self-insured employer markets as they are eager to offer more cost-effective and clinically proven solutions for treating these conditions.”
Mobile Wireless Device companies raised $400 million in 1H 2021, according to Mercom’s 1H 2021 Digital Health Funding and M&A Report.
